Most Cited Articles

Diverse mechanisms of AKT pathway activation in human malignancy

, 2013; 13(3): 234-244

Cheung M., Testa J.R.

DOI: 10.2174/1568009611313030002

P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: Current status and future perspectives

, 2013; 13(3): 326-346

Binkhathlan Z., Lavasanifar A.

DOI: 10.2174/15680096113139990076

Oxygen-independent regulation of HIF-1: Novel involvement of PI3K/ AKT/mTOR pathway in cancer

, 2013; 13(3): 245-251

Agani F., Jiang B.-H.

DOI: 10.2174/1568009611313030003

Nanomedicines as cancer therapeutics: Current status

, 2013; 13(4): 362-378

Akhter S., Ahmad I., Ahmad M.Z., Ramazani F., Singh A., Rahman Z., Ahmad F.J., Storm G., Kok R.J.

DOI: 10.2174/1568009611313040002

The miR-183/96/182 cluster regulates oxidative apoptosis and sensitizes cells to chemotherapy in gliomas

, 2013; 13(2): 221-231

Tang H., Biana Y., Tu C., Wang Z., Yu Z., Liu Q., Xu G., Wu M., Li G.

DOI: 10.2174/1568009611313020010

Novel approaches for molecular targeted therapy of breast cancer: Interfering with PI3K/AKT/mTOR signaling

, 2013; 13(2): 188-204

Grunt T.W., Mariani G.L.

DOI: 10.2174/1568009611313020008

VEGF in tumor progression and targeted therapy

, 2013; 13(4): 423-443

Chekhonin V.P., Shein S.A., Korchagina A.A., Gurina O.I.

DOI: 10.2174/15680096113139990074

DNA methyltransferase-1 inhibitors as epigenetic therapy for cancer

, 2013; 13(4): 379-399

Singh V., Sharma P., Capalash N.

DOI: 10.2174/15680096113139990077

Current status and future perspectives of PI3K and mTOR inhibitor as anticancer drugs in breast cancer

, 2013; 13(2): 175-187

Zhang X., Li X.-r., Zhang J.

DOI: 10.2174/1568009611313020007

Targeting tyrosine kinase receptors in hepatocellular carcinoma

, 2013; 13(3): 300-312

Muntane J., De la Rosa A.J., Docobo F., Garcia-Carbonero R., Padillo F.J.

DOI: 10.2174/15680096113139990075

Webmaster Contact:
Copyright © 2018 Bentham Science